Ayurvedic Management of Recurrent Abortions due to Uterine Fibroid.

Shailendra Dadarao Katakdound
{"title":"Ayurvedic Management of Recurrent Abortions due to Uterine Fibroid.","authors":"Shailendra Dadarao Katakdound","doi":"10.4103/asl.ASL_189_15","DOIUrl":null,"url":null,"abstract":"<p><p>Uterine fibroids are present in 30-70% of women of reproductive age. Uterine fibroids distort the uterine cavity. Therefore there is consensus of a negative impact on both the clinical pregnancy and delivery rates.[2] In addition, studies have also reported an increased risk of spontaneous miscarriage with submucosal fibroids. In biomedicine, myomectomy is considered the treatment of choice and Assisted Reproductive Technology is advised to overcome infertility. In Hārita Saṃhitā treatment is given for recurrent abortion (<i>Garbhasrāvī</i>). In this study, considering <i>pitta doṣa</i> and altered uterine receptivity (<i>kṣetra duṣṭi</i>) as causative factors, purgation (<i>virecana karma</i>) was done, enema (<i>yoga basti</i>) was given after post purgation protocol (<i>saṃsarjana karma</i>). After body purification (<i>śodhana</i>), <i>garbhasthāpaka</i> drugs were given to the patient for one month. Patient conceived in the second month with this treatment. In Antenatal Care, haematinics and calcium supplements and month wise Ayurvedic medication (<i>Māsānumāsika kaṣāya</i>) were given for nine months. Elective caesarean section ắs done after GA 38 weeks (USG) followed by inj. Wymesone 8 mg. The procedure uneventful. Thus proving Ayurvedic management of recurrent abortion due to uterine fibroid. It is cost effective and improves and normalises uterine receptive environment.</p>","PeriodicalId":7805,"journal":{"name":"Ancient Science of Life","volume":"36 3","pages":"159-162"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566827/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ancient Science of Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/asl.ASL_189_15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Uterine fibroids are present in 30-70% of women of reproductive age. Uterine fibroids distort the uterine cavity. Therefore there is consensus of a negative impact on both the clinical pregnancy and delivery rates.[2] In addition, studies have also reported an increased risk of spontaneous miscarriage with submucosal fibroids. In biomedicine, myomectomy is considered the treatment of choice and Assisted Reproductive Technology is advised to overcome infertility. In Hārita Saṃhitā treatment is given for recurrent abortion (Garbhasrāvī). In this study, considering pitta doṣa and altered uterine receptivity (kṣetra duṣṭi) as causative factors, purgation (virecana karma) was done, enema (yoga basti) was given after post purgation protocol (saṃsarjana karma). After body purification (śodhana), garbhasthāpaka drugs were given to the patient for one month. Patient conceived in the second month with this treatment. In Antenatal Care, haematinics and calcium supplements and month wise Ayurvedic medication (Māsānumāsika kaṣāya) were given for nine months. Elective caesarean section ắs done after GA 38 weeks (USG) followed by inj. Wymesone 8 mg. The procedure uneventful. Thus proving Ayurvedic management of recurrent abortion due to uterine fibroid. It is cost effective and improves and normalises uterine receptive environment.

子宫肌瘤复发性流产的阿育吠陀治疗。
30-70%的育龄妇女存在子宫肌瘤。子宫肌瘤使子宫腔变形。因此,对临床妊娠率和分娩率的负面影响是一致的。[2]此外,研究还报道了粘膜下肌瘤自发性流产的风险增加。在生物医学中,子宫肌瘤切除术被认为是治疗不孕症的选择,辅助生殖技术被建议克服不孕症。在Hārita Saṃhitā对复发性流产给予治疗(Garbhasrāvī)。在本研究中,考虑到皮塔doṣa和子宫容受性改变(kṣetra duṣṭi)为致病因素,进行了净化(virecana karma),在净化后的方案(saṃsarjana karma)后给予灌肠(basti yoga)。身体净化后(śodhana), garbhasthāpaka用药1个月。患者在接受这种治疗的第二个月受孕。在产前护理方面,提供了九个月的血液和钙补充剂以及每月的阿育吠陀药物(Māsānumāsika kaṣāya)。妊娠38周(USG)后择期剖宫产ắs。怀美酮8毫克。整个过程平安无事。从而证明阿育吠陀治疗子宫肌瘤所致复发性流产。它具有成本效益,改善和正常化子宫接受环境。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
39 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信